On 28 February 2026, India launched its first national human papillomavirus (HPV) vaccination programme, marking a significant milestone in the country’s effort to reduce the burden of cervical cancer. This initiative was implemented eight years after the National Technical Advisory Group on Immunisation (NTAGI) first recommended the vaccine’s inclusion in the Universal Immunisation Programme.
Cervical cancer remains the fourth most common cancer in women worldwide, with India accounting for approximately 13% of the global burden. A narrative review published in Infectious Agents and Cancer synthesises the evidence base underpinning this national immunisation decision. The review examines six key domains, including HPV virology, vaccine pharmacology, global efficacy trials, safety evidence, international introduction experiences, and cost-effectiveness.
The efficacy of single-dose HPV vaccination is supported by three independent, prospectively followed cohorts in India, Kenya, and Costa Rica. These datasets, including the KEN SHE trial in Kenya and the ESCUDDO trial in Costa Rica, demonstrate high and concordant protection over the completed follow-up periods. The World Health Organization recommended single-dose regimens in 2022, and subsequent reports from these regions have further strengthened the evidence base.
Safety concerns have been extensively addressed through large-scale pharmacovigilance data. Two Scandinavian cohorts, with a combined study population exceeding four million women, found no safety signal warranting a change in policy. Of these, just over half a million were vaccinated. The adverse events that commonly occur are injection-site reactions and vasovagal syncope, rather than the rare serious outcomes that often drive public concern.
Register data from early-vaccinated cohorts in England and Sweden show observed cervical cancer reductions of 87% and 88%, respectively. In England, girls were offered the vaccine at age 12–13, while in Sweden, women were vaccinated before age 17. These findings highlight that the age of vaccination materially determines the eventual impact of a national programme. Modelled projections suggest that further reductions in cervical cancer incidence are possible with sustained vaccine coverage.
Despite the strong evidence supporting the vaccination decision, the specific design of India’s rollout presents certain challenges. The programme targets a single-age cohort, and the choice of an imported vaccine over the newly trialled indigenous Cervavac vaccine has been noted. Additionally, the eight-year gap between the initial recommendation and the launch reflects resource and institutional constraints rather than scientific uncertainty.
Screening remains a major gap in India’s cervical cancer control efforts. The last survey estimate from NFHS-5 in 2019-21 indicated a screening rate of about 2%, against a 70% WHO target. Programme data use a different indicator and denominator, which complicates direct comparisons.
The review concludes that two priorities remain open for India: closing the screening gap and developing a funded, time-bound plan to transition from GAVI-donated supply to domestic manufacture.
At the biological level, the review details how HPV vaccination prevents cervical cancer through a well-characterised mechanism involving VLP-induced neutralising antibody against the L1 capsid antigen. This protective biological pathway is backed by two decades of converging efficacy data across three successive vaccine generations. When examining single-dose schedules, the researchers noted that the Indian cohort has provided critical evidence through extended follow-up spanning 12 to 15 years, demonstrating concordant protection alongside the KEN SHE trial in Kenya and the ESCUDDO trial in Costa Rica.
To evaluate delivery strategies across diverse health systems, the synthesis examined the practical introduction experiences of eight national programmes: Australia, England, Sweden, Rwanda, Bhutan, Kenya, Japan, and India. The authors compiled this cross-domain assessment by searching the PubMed and Scopus databases, supplementing peer-reviewed publications with independently verified grey literature to examine how pharmacology, trial results, pharmacovigilance cohorts, and cost-effectiveness analysis collectively inform national immunisation choices.
Subject of Research: India's national HPV vaccination programme and supporting evidence
Article Title: From virus to vaccination: a comprehensive review of Human Papilloma Virus (HPV) vaccine and introduction to India’s national HPV vaccination initiative
Article References: Bangla, S., & Potarad, K. P. (2026). From virus to vaccination: a comprehensive review of Human Papilloma Virus (HPV) vaccine and introduction to India’s national HPV vaccination initiative. Infectious Agents and Cancer. https://doi.org/10.1186/s13027-026-00810-2
Image Credits: AI Generated
DOI: 10.1186/s13027-026-00810-2
Keywords: HPV vaccination, cervical cancer, India, public health, single-dose vaccine, pharmacovigilance, cervical cancer screening, vaccine policy, Infectious Agents and Cancer, NTAGI, Cervavac, WHO recommendations, vaccine efficacy, vaccine safety, global health, immunisation programme, cancer prevention, virology, health policy, vaccine rollout
News Source: Nathaniel Bowman. (November 20, 2026). India Launches National HPV Vaccination Programme. Scienmag.



